Bright Minds Biosciences, Inc. (DRUG)
52.43
+0.43
(+0.83%)
USD |
NASDAQ |
Oct 08, 16:00
52.43
0.00 (0.00%)
After-Hours: 16:49
Bright Minds Biosciences Total Liabilities (Quarterly) : 1.793M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.793M |
| March 31, 2026 | 2.746M |
| December 31, 2025 | 1.167M |
| September 30, 2025 | 1.708M |
| June 30, 2025 | 0.4894M |
| March 31, 2025 | 0.505M |
| December 31, 2024 | 0.3974M |
| September 30, 2024 | 0.4206M |
| June 30, 2024 | 0.1305M |
| March 31, 2024 | 0.625M |
| December 31, 2023 | 0.6478M |
| September 30, 2023 | 0.2077M |
| Date | Value |
|---|---|
| June 30, 2023 | 0.5553M |
| March 31, 2023 | 0.7688M |
| December 31, 2022 | 0.43M |
| September 30, 2022 | 1.124M |
| June 30, 2022 | 0.2987M |
| March 31, 2022 | 0.8034M |
| December 31, 2021 | 0.3876M |
| September 30, 2021 | 0.5041M |
| June 30, 2021 | 0.2607M |
| March 31, 2021 | 0.3256M |
| December 31, 2020 | 0.0749M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Amgen, Inc. | 83.95B |
| Lineage Cell Therapeutics, Inc. | 46.42M |
| Recursion Pharmaceuticals, Inc. | 297.66M |
| Agenus, Inc. | 378.54M |
| BioCryst Pharmaceuticals, Inc. | 1.012B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 218.74M |
| Shareholders Equity (Quarterly) | 216.95M |
| Debt to Equity Ratio | 0.0002 |
| Current Ratio | 121.98 |
| Net Debt Paydown Yield | 0.00% |